EP1442039A1 - Derives de pyrimido (4,5-b) indole - Google Patents

Derives de pyrimido (4,5-b) indole

Info

Publication number
EP1442039A1
EP1442039A1 EP02777332A EP02777332A EP1442039A1 EP 1442039 A1 EP1442039 A1 EP 1442039A1 EP 02777332 A EP02777332 A EP 02777332A EP 02777332 A EP02777332 A EP 02777332A EP 1442039 A1 EP1442039 A1 EP 1442039A1
Authority
EP
European Patent Office
Prior art keywords
pyrimido
indole
carbamoyl
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02777332A
Other languages
German (de)
English (en)
Inventor
Timothy Lowinger
Makoto Shimazaki
Hiroki Sato
Kazuho Tanaka
Naoki Tsuno
Karsten Marx
Masaru Yamamoto
Klaus Urbahns
Florian Gantner
Hiromi Okigami
Kosuke Nakashima
Keisuke Takeshita
Kevin B. Bacon
Hiroshi Komura
Nagahiro Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001334662A external-priority patent/JP2003137886A/ja
Priority claimed from GB0214544A external-priority patent/GB2390090A/en
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1442039A1 publication Critical patent/EP1442039A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to pyrimido[4,5-b]indoles which are useful as an active ingredient of pharmaceutical preparations.
  • the pyrimido[4,5-b]indoles of the present invention have MKK7 and KK4 [MAPK (mitogen activated protein kinase) kinase
  • inhibitory activity can be used for the prophylaxis and treatment of diseases associated with MKK7 and MKK4 activity.
  • the pyrimido[4,5-b]indoles derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic rhinitis, allergic diseases, COPD, septic shock, arthritis, joint diseases and myocardial injuries, as well as autoimmune pathologies such as rheumatoid arthritis, Grave's disease, and atherosclerosis.
  • diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic rhinitis, allergic diseases, COPD, septic shock, arthritis, joint diseases and myocardial injuries, as well as autoimmune pathologies such as rheumatoid arthritis, Grave's disease, and atherosclerosis.
  • the compounds of the present invention are also useful for treatment of ischemia, myocardial injury, pulmonary hypertension, renal failure, Huntington's chorea and cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and focal ischemia, since the diseases also relate to MKK7 and/or MKK4.
  • the mitogen-activated protein kinases are a family of serine/threonine kinases involved in the transduction of signals from the cell membrane to the nucleus in response to various types of stimuli such as lipopolysaccharide (LPS), tumor necrosis factor- ⁇ (TNF- ), interleukins, CD40 and others. These kinases participate in a wide variety of signaling cascades controlling cellular events such as cell growth, differentiation, activation, apoptosis, stress responses, and transformation.
  • LPS lipopolysaccharide
  • TNF- tumor necrosis factor- ⁇
  • CD40 interleukins
  • MAPK extracellular-regulated kinases
  • ERK extracellular-regulated kinases
  • MAPK/JNK stress-activated/c-jun N-terminal kinase
  • SAPK/JNKs are activated in response to cellular "stress” such as changes in osmolarity or metabolism, ischemia, heat shock, shear stress, ceramide or inflammatory cytokines (TNF- ⁇ , IL-1).
  • stress such as changes in osmolarity or metabolism, ischemia, heat shock, shear stress, ceramide or inflammatory cytokines (TNF- ⁇ , IL-1).
  • JNKs control gene activity via phosphorylation of a variety of transcriptional factors including c-Jun, JunD, nuclear factor of activated T cells (NFAT)4, or Elk-1 , all present in immune cells and known to regulate the transcription of many genes during an inflammatory response.
  • SAPK/JNKs regulate the activation and proliferation of T and B lymphocytes, activation of mast cells
  • MKK stress kinase mitogen-activated protein kinase kinase
  • MAPKs themselves require dual phosphorylation of both threonine and tyrosine at their so-called Thr-X-Tyr motif, wliich is brought upon by the upstream regulators MAPK kinases (MKKs).
  • MKK1-MKK7 MEK1, MEK2,
  • MKK3, MKK4, MEK5, MKK6, and MKK7 are known to date with MKK7 being the most recently identified (Tournier C, Whitmarsh J., Cavanagh J., Barrett T.,
  • Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2- terminal kinase. Proc Natl Acad Sci USA, 94: 7337-7342, 1997), (Moriguchi T.,
  • MKK4 is also capable of phosphorylating p-38 MAP kinases.
  • p-38 kinases are also involved in the control of inflammatory gene expression, especially after stimulation of cells with lipopoly saccharide and cytokines (Han J., Lee JD., Jiang Y., Li Z., Feng L., Ulevitch RJ.
  • p38 controls the release of IL-12 and IFN ⁇ and in B cells, CD40 cross-linking leads to rapid p38 activation and thus controls proliferation, and adhesion molecule expression.
  • p38 MAPK are activated by hypoxia and, by controlling the transcription factor ATF2, play a role in neuronal development and survival (Lee JC, Kumar S., Griswold DE., Underwood DC, Notta BJ., Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology, Al: 185-201, 2000).
  • a specific inhibitor of MKK7 and/or of MKK4, which is expected to block the synthesis of pro-inflammatory cytokines and the activation of various immune cells, should have a broad anti-inflammatory profile with potential for the treatment of inflammatory and immunoregulatory disorders and diseases, including asthma, rhinitis, allergic diseases, septic shock, joint diseases and myocardial injuries, as well as autoimmune pathologies such as rheumatoid arthritis, Grave's disease, and atherosclerosis.
  • inhibitors should also have therapeutic potential for the treatment of renal failure, Huntington's chorea, cardiac hypertrophy and neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and focal ischemia (Xia XG., Harding T., Weller M., Bieneman A., Uney JB., Schulz JB. Gene transfer of the JNK interacting protein- 1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA, 98: 10433-10438, 2001).
  • WO 9842708 discloses anti-asthma agent represented by the general formula:
  • R a , R 2 ⁇ , R 2"la , R 2"2a , R 3'la , and R 3"2a are defined in the application.
  • WO 9626941 discloses pharmaceutical agents represented by the general formula:
  • R lc , R 2c , R 3c , R 4c , R 5c and R 6c are defined in the specification.
  • WO 9320078 discloses pharmaceutically active compound represented by the formula:
  • IN 157280 discloses the method for preparing anti hypertension agents represented by the formula:
  • R le , R 2e , R 3e , R 4e , and R 5e are defined in the specification.
  • WO 97/02266 discloses anti-hyperproliferative disease agents represented by the general formula:
  • WO 98/43973 also discloses anti-proliferative disease agents represented by the general formula:
  • Rid, R2d, R3d, R4', q and m' are defined in the application.
  • This invention is to provide a novel pyrimido[4,5-b]indole derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:
  • R is hydrogen, amino, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C -6 )alkynyl, halogen substituted (C 1-6 ) alkyl, cyano, cyano(C 1-6 )alkyl, (C -8 )cycloalkyl, nitro, nitro(C 1 .. 6 )alkyl or fluoro;
  • R 2 and R 3 independently represent hydrogen, (C 2 - 6 )alkenyl, (C 2-6 )alkynyl,
  • R 2 and R 3 are taken together with the attached nitrogen atom to form a 3-8 membered saturated ring optionally interrupted by one or two atoms selected from the group consisting of oxygen, sulfur and nitrogen,
  • said saturated ring is optionally fused by benzene or 3-8 membered saturated ring having 0 to 3 nitrogen atoms,
  • said saturated ring is optionally having substituents independently selected from the group consisting of halogen, hydroxy, carbamoyl, carboxy, amino, oxo, pyrrolidino, (C 1-6 )alkoxy, (C 2-6 )alkenyl, (C 2-6 )- alkynyl, (C 3-8 )cycloalkyl, (C 1-6 )alkylcarbonyl, (C 1-6 )alkylsulfonyl, arylsulfonyl, (C 1-6 )alkyl, hydroxy(C 1-6 )alkyl, (C 1-6 )alkoxy(C 1-6 )alkyl, (C 1-6 )alkoxycarbonyl, (C 1-6 )alkoxycarbonyl(C ⁇ -6 )alkyl, (C 3- )cyclo- alkyl(C 1-6 )alkyl, aryl(C 1-6 )alkyl, carbamoyl(C 1-6
  • spiro ring is optionally interrupted by 0 to 3 nitrogen or oxygen atoms
  • R 4 is halogen, hydroxy, (C 1-6 )alkyl, amino (C 1-6 )alkyl, (C 1-6 )alkoxy, cyano, carboxy, (C 1-6 )alkoxycarbony, or carbamoyl;
  • R 5 is hydrogen, or (C 1-6 )alkyl.
  • Alkyl per se and "alk” and “alkyl” in alkoxy, alkanoyl, alkylamino, alkylamino- carbonyl, alkylaminosulphonyl, alkylsulphonylamino, alkoxycarbonyl, alkoxy- carbonylamino and alkanoylamino represent a linear or branched alkyl radical having generally 1 to 6, preferably 1 to 4 and particularly preferably 1 to 3 carbon atoms, representing illustratively and preferably methyl, ethyl, n-propyl, isopropyl, tert- butyl, n-pentyl and n-hexyl.
  • Alkoxy illustratively and preferably represents methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
  • Alkanoyl illustratively and preferably represents acetyl and propanoyl.
  • Alkylamino represents an alkylamino radical having one or two (independently selected) alkyl substituents, illustratively and preferably representing methylamino, ethylainino, n-propylamino, isopropylamino, tert-butylamino, n-pentylamino, n- hexyl-amino, N,N-dimethylamino, N,N-diethylamino, N-ethyl-N-methylamino, N- methyl-N-n-propylamino, N-isopropyl-N-n-propylamino, N-t-butyl-N-methylamino, N-ethyl-N-n-pentylamino and N-n-hexyl-N-methylamino.
  • Alkylaminocarbonyl or alkylcarbamoyl represents an alkylammocarbonyl radical having one or two (independently selected) alkyl substituents, illustratively and preferably representing methylaminocarbonyl, ethylaminocarbonyl, n-propylamino- carbonyl, isopropylamino-carbonyl, tert-butylaminocarbonyl, n-pentylamino- carbonyl, n-hexylaminocarbonyl, N,N-dimethylaminocarbonyl, N,N-diethylamino- carbonyl, N-ethyl-N-methylaminocarbonyl, N-methyl-N-n-propylaminocarbonyl, N- isopropyl-N-n-propylaminocarbonyl, N-t-butyl-N-methylaminocarbonyl, N-ethyl-N- n-
  • Alkylaminosulphonyl represents an alkylaminosulphonyl radical having one or two (independently selected) alkyl substituents, illustratively and preferably representing methylaminosulphonyl, ethylaminosulphonyl, n-propylaminosulphonyl, isopropyl- aminosulphonyl, tert-butylaminosulphonyl, n-pentylaminosulphonyl, n-hexyl-amino- sulphonyl, N,N-dimethylaminosulphonyl, N,N-diethylaminosulphonyl, N-ethyl-N- methylamino-sulphonyl, N-methyl-N-n-propylaminosulphonyl, N-isopropyl-N-n-propylaminosulphonyl, N-t-butyl-N-methylaminosulphonyl, N-ethy
  • Alkylsulphonylamino illustratively and preferably represents methylsulphonylamino, ethylsulphonylamino, n-propylsulphonylamino, isopropylsulphonylamino, tert-butyl- sulphonylamino, n-pentylsulphonylamino and n-hexylsulphonylamino.
  • Alkoxycarbonyl illustratively and preferably represents methoxycarbonyl, ethoxy- carbonyl, n-propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, n-pentoxy- carbonyl and n-hexoxycarbonyl.
  • Alkoxycarbonylamino illustratively and preferably represents methoxycarbonylamino, ethoxycarbonylamino, n-propoxycarbonylamino, isopropoxycarbonylamino, tert-butoxycarbonylamino, n-pentoxycarbonylamino and n-hexoxycarbonylamino .
  • Alkanoylamino illustratively and preferably represents acetylamino and ethyl- carbonylamino.
  • Cycloalkyl per se and in cycloalkylamino and in cycloalkylcarbonyl represents a cycloalkyl group having generally 3 to 8 and preferably 5 to 7 carbon atoms, illustratively and preferably representing cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Cycloalkylamino represents a cycloalkylamino radical having one or two (independently selected) cycloalkyl substituents, illustratively and preferably representing cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino and cyclo- heptylamino.
  • Cycloalkylcarbonyl illustratively and preferably represents cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl and cycloheptyl- carbonyl.
  • Aryl per se and in arylamino and in arylcarbonyl represents a mono- to tricyclic aromatic carbocyclic radical having generally 6 to 14 carbon atoms, illustratively and preferably representing phenyl, naphthyl and phenanthrenyl.
  • Arylamino represents an arylamino radical having one or two (independently selected) aryl substituents, illustratively and preferably representing phenylamino, diphenylamino and naphthylamino.
  • Arylcarbonyl illustratively and preferably represents phenylcarbonyl and naphthyl- carbonyl.
  • Heteroaryl per se and in heteroarylamino and heteroarylcarbonyl represents an aromatic mono- or bicyclic radical having generally 5 to 10 and preferably 5 or 6 ring atoms and up to 5 and preferably up to 4 hetero atoms selected from the group consisting of S, O and N, illustratively and preferably representing thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl.
  • Heteroarylamino represents an heteroarylamino radical having one or two (independently selected) heteroaryl substituents, illustratively and preferably representing thienylamino, furylamino, pyrrolylamino, thiazolylamino, oxazolylamino, imidazolyl-amino, pyridylamino, pyrimidylamino, pyridazinylamino, indolylamino, indazolylamino, benzofuranylamino, benzothiophenylamino, quinolinyl-amino, isoquinolinylamino .
  • Heteroarylcarbonyl illustratively and preferably represents thienylcarbonyl, furyl- carbonyl, pyrrolylcarbonyl, thiazolylcarbonyl, oxazolylcarbonyl, imidazolyl- carbonyl, pyridylcarbonyl, pyrimidylcarbonyl, pyridazinylcarbonyl, indolylcarbonyl, indazolylcarbonyl, benzofiiranylcarbonyl, benzothiophenylcarbonyl, quinolinyl- carbonyl, isoquinolinylcarbonyl.
  • Heterocyclyl per se and in heterocyclylcarbonyl represents a mono- or polycyclic, preferably mono- or bicyclic, nonaromatic heterocyclic radical having generally 4 to 10 and preferably 5 to 8 ring atoms and up to 3 and preferably up to 2 hetero atoms and or hetero groups selected from the group consisting of N, O, S, SO and SO 2 .
  • the heterocyclyl radicals can be saturated or partially unsaturated.
  • Heterocyclylcarbonyl illustratively and preferably represents tetrahydrofuran-2- carbonyl, pyrrolidine-2-carbonyl, pyrrolidine-3 -carbonyl, pyrrolinecarbonyl, piperidinecarbonyl, morpholinecarbonyl, perhydroazepinecarbonyl.
  • Halogen represents fluorine, chlorine, bromine and iodine.
  • This invention is also to provide a method for treating or preventing a disorder or disease associated with MKK7 and/or MKK4 activity in a human or animal subject, comprising administering to said subject a therapeutically effective amount of the pyrimido[4,5-b]indole derivative shown in the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof.
  • this invention is to provide a use of the pyrimido[4,5-b]indole derivative shown in the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof in the preparation of a medicament.
  • said medicament is suitable for treating or preventing a disorder or disease associated with MKK7 and/or MKK4 activity.
  • the compounds of the present invention surprisingly show excellent MKK7 and/or MKK4 inhibitory activity. They are, therefore, suitable for the production of medicament or medical composition, which may be useful to treat MKK7 and/or MKK4 related diseases.
  • the pyrirnido[4,5-b]indoles derivatives of the present invention inhibit MKK7 and/or MKK4, they are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic rhinitis, allergic diseases, COPD, septic shock, arthritis, joint diseases and myocardial injuries, as well as autoimmune pathologies such as rheumatoid arthritis, Grave's disease, and atherosclerosis.
  • diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic rhinitis, allergic diseases, COPD, septic shock, arthritis, joint diseases and myocardial injuries, as well as autoimmune pathologies such as rheumatoid arthritis, Grave's disease, and atherosclerosis.
  • MKK7 and/or MKK4 is an important target and inhibition of MKK7 and/or MKK4 is likely to be effective in the treatment of such inflammatory and immunoregulatory disorders and diseases.
  • the compounds of the present invention are also useful for treatment of ischemia, myocardial injury, pulmonary hypertension, renal failure, Huntington's chorea and cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and focal ischemia, since the diseases also relate to MKK7 and/or MKK4.
  • the compounds of formula (I) are those wherein:
  • R 1 is amino
  • R 2 is pyrrolidyl(C 1-6 )alkyl, saturated(C 3-8 )cycloalkyl or benzyl, and
  • R 3 is hydrogen, (C 1-6 )alkyl, or benzyl
  • R 2 and R 3 are taken together with the attached nitrogen atom to form
  • a 7 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen, sulfur and nitrogen, a 5-7 membered saturated heterocyclic ring which is fused by benzene or saturated(C 3-8 )cycloalkyl,
  • a 8-12 membered spiro ring optionally interrupted by one or two oxygen atoms;
  • the compounds of formula (I) are those wherein:
  • R 1 is amino
  • R is carbamoyl or amino (C 1-6 )alkyl
  • R 5 is hydrogen or (C ⁇ -6 )alkyl.
  • the compounds of formula (I) are those wherein:
  • R 4 is carbamoyl
  • R 5 is hydrogen
  • the compounds of formula (I) are those wherein:
  • R 1 is hydrogen, methyl or amino
  • R 4 is carbamoyl
  • R is hydrogen
  • the compounds of formula (I) are those wherein: R 2 and R 3 independently represent hydrogen, (C 1-6 )alkyl optionally substituted by amino, hydroxy, methoxy, imidazolyl, (C 1-6 )alkoxy or (C 1-6 )alkoxycarbonyl,
  • (C 3-8 )cycloalkyl optionally substituted by hydroxy or hydroxy (C 1-6 )alkyl, benzyl, or 5-7 membered saturated heterocyclic ring interrupted by one or two oxygen atoms;
  • R 2 and R 3 are taken together with the attached nitrogen atom to form a saturated heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, piperazino, homopiperidino, and morpholino
  • heterocyclic ring is optionally substituted by amino, methylamino, acetamido, hydroxy, oxo, carbamoyl, benzyl, bromo, carboxy, pyrrolidino, or (C 1-6 )alkyl optionally substituted by hydroxy, amino or carboxy,
  • heterocyclic ring is optionally fused by benzene or saturated(C 3-8 )- cycloalkyl
  • R is carbamoyl or amino(C ⁇ -6 )alkyl
  • R 5 is hydrogen
  • the compounds of formula (I) are those wherein:
  • R 1 is hydrogen, methyl or amino
  • R 2 and R 3 independently represent hydrogen, (C 1-6 )alkyl optionally substituted by amino, hydroxy, methoxy, imidazolyl, (C ⁇ -6 )alkoxy or (C -8 )cycloalkyl optionally substituted by hydroxy or hydroxy (C 1-6 )alkyl, benzyl, or 5-7 membered saturated heterocyclic ring interrupted by one or two oxygen atoms;
  • R 2 and R 3 are taken together with the attached nitrogen atom to form a saturated heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, piperazino, homopiperidino, and morpholino
  • heterocyclic ring is optionally substituted by amino, methylamino, acetamido, hydroxy, oxo, carbamoyl, benzyl, bromo, carboxy, pyrrolidino, or (C 1-6 )alkyl optionally substituted by hydroxy, amino or carboxy,
  • heterocyclic ring is optionally fused by benzene or saturated(C 3-8 )- cycloalkyl
  • R is carbamoyl
  • R 5 is hydrogen
  • the compounds of formula (I) are those wherein:
  • R 1 is amino
  • R 2 is saturated(C 3-8 )cycloalkyl or benzyl;
  • R 3 is hydrogen, or (C 1-6 )alkyl,
  • R 2 and R 3 are taken together with the attached nitrogen atom to form
  • heterocyclic ring is selected from the group consisting of pyrrolidino, piperidino, piperazino, homopiperidino, and morpholino,
  • R is hydrogen
  • the compounds of formula (I) are those wherein:6- Carbamoyl-4-( 1 -piperidinyl)-9H-pyrimido [4,5 -bjindole,
  • 6-Carbamoyl-4 (4-hydroxy-l-piperidinyl)-9H-pyrimido[4,5-b]indole, 6-Carbamoyl-4- (cycloheptylamino)-9H-pyrimido[4,5-b]indole, 6-Carbamoyl-4- ⁇ (4-methyl- 1 -piperidinyl)-9H-pyrimido [4,5 -b]indole, 6-Carbamoyl-4 (3-methyl-l-piperidinyl)-9H-pyrimido[4,5-b]indole, 6-Carbamoyl-4 (3,5-dimethyl-l-pi ⁇ eridinyl)-9H-pyrimido[4,5-b]indole,
  • 6-Carbamoyl-4 [2-(hydroxymethyl)-l-pi ⁇ eridinyl]-9H-pyrimido[4,5-b]indole, 6-Carbamoyl-4- (cyclo ⁇ entylamino)-9H-pyrimido[4,5-b]indole, 6-Carbamoyl-4- -(l-azepanyl)-9H-pyrimido[4,5-b]indole,
  • the present invention provides a medicament which include one of the compounds described above and optionally pharmaceutically acceptable excipient.
  • the compound of the formula (I) of the present invention can be, but not limited to be, prepared by combining various known methods.
  • one or more of the substituents, such as amino group, carboxyl group, and hydroxyl group of the compounds used as starting materials or intermediates are advantageously protected by a protecting group known to those skilled in the art. Examples of the protecting groups are described in "Protective Groups in Organic Synthesis (2nd Edition)" by Greene and Wuts.
  • the compound of the formula (I) of the present invention can be, but not limited to be, prepared by the method [A] below.
  • the compound (I) (wherein R 1 , R 2 , R 3 , R 4 and R 5 are the same as defined above) or a salt thereof, for example, can be prepared by the reaction of the compound of formula (II) (wherein R 1 , R 4 and R 5 are the same as defined above, and L represents leaving group including, for instance, halogen atom such as chlorine, bromine, or iodine atom; C 6-10 arylsulfonyloxy group such as benzenesulfonyloxy or p-toluene- sulfonyloxy; C 1-4 alkylsulfonyloxy group such as methanesulfonyloxy; and halogen substituted C 1-4 alkylsulfonyloxy group such as trifluoromethanesulfonyloxy and the like.) or a salt thereof, with a compound shown by the general formula (III) (wherein R 2 and R 3 are the same as defined above ) or
  • This reaction can be carried out without solvent or in a solvent including, for instance, alcohol such as methanol and ethanol; ethers, such as dioxane, diethyl ether, and tetrahydrofuran (THF); aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as dimethylformamide (DMF) and dimethylacetamide; sulfoxides such as dimethyl sulfoxide, and others.
  • a solvent including, for instance, alcohol such as methanol and ethanol; ethers, such as dioxane, diethyl ether, and tetrahydrofuran (THF); aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as dimethylformamide (DMF) and dimethylacetamide; sulfoxides such as dimethyl sul
  • the reaction temperature can be optionally set depending on the compounds to be reacted.
  • the reaction temperature is usually, but not limited to, about 10°C to 200°C and preferably about 20°C to 100°C
  • the reaction may be conducted for, usually, 30 mins to 48 hrs and preferably 1 hr to 24 hrs.
  • the reaction can be advantageously conducted in the presence of a base.
  • a base examples include an alkali metal hydride such as sodium hydride or potassium hydride; alkali metal alkoxide such as sodium methoxide or sodium ethoxide; alkali metal hydroxide such as sodium hydroxide or potassium hydroxide; carbonates such as sodium carbonate or potassium carbonate, and bicarbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate; organic amines such as triethylamine.
  • the amine (III) are commercially available or can be synthesized by conventional methods. If required, R 1 , R 2 , R 3 , R 4 and R 5 can be optionally protected during the reaction and deprotected afterward.
  • the compound of the formula (I-a) can be, but not limited to be, prepared by the methods [B] or [C] below. Method [B]
  • the compound of formula (I-a) (wherein R 1 , R 2 , R 3 and R 5 are the same as defined above) can be prepared by the reaction of the compound of formula (I-b)(wherein R 1 ,
  • R 2 , R 3 and R 5 are the same as defined above, and X represents hydrogen or (C 1-6 )- alkyl) and ammonia.
  • the reaction can be carried out without solvent or in a solvent including, for instance, alcohols such as methanol and ethanol, 1 -propanol, isopropanol and tert-butanol; water; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; amides such as N, N-dimethylformamide (DMF), N, N-dimethyl- acetamide; sulfoxides such as dimethyl sulfoxide, and others.
  • a solvent including, for instance, alcohols such as methanol and ethanol, 1 -propanol, isopropanol and tert-butanol; water; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydro
  • the reaction temperature can be optionally set depending on the compounds to be reacted.
  • the reaction temperature is usually, but not limited to, about 0°C to 60°C
  • the reaction may be conducted for, usually, 30 mins to 48 hrs and preferably 1 hr to 24 hrs.
  • the reaction can be advantageously carried out using coupling agent including, for instance, carbo- diimides such as N, N-dicyclohexylcarbodiimide and l-(3-dimethylaminopropyl)-3- ethylcarbodiimide; carbonyldiazoles such as l,l'-carbonyldi(l,3-imiazole)(CDI) and l,l'-carbonyldi(l,2,4-triazole)(CDT), and others.
  • coupling agent including, for instance, carbo- diimides such as N, N-dicyclohexylcarbodiimide and l-(3-dimethylaminopropyl)-3- ethylcarbodiimide; carbonyldiazoles such as l,l'-carbonyldi(l,3-imiazole)(CDI) and l,l'-carbonyldi(l,2,4-triazole)(CD
  • the compound of formula (I-a) (wherein R , R 2 , R 3 and R 5 are the same as defined above) can be prepared by the hydrolysis of the compound of formula (I-c) (wherein R 1 , R 2 , R 3 and R 5 are the same as defined above).
  • the reaction can be carried out in a solvent including, for instance, alcohols such as methanol and ethanol, 1 -propanol, isopropanol, n-butanol and tert-butanol; water; ketone such as acetone; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; amides such as N, N-dimethylformamide (DMF), N, N- dimethylacetamide, and others.
  • a solvent including, for instance, alcohols such as methanol and ethanol, 1 -propanol, isopropanol, n-butanol and tert-butanol; water; ketone such as acetone; ethers such as diethyl ether, isopropyl ether
  • the reaction temperature can be optionally set depending on the compounds to be reacted.
  • the reaction temperature is usually, but not limited to, about 0°C to 60°C
  • the reaction may be conducted for, usually, 30 mins to 48 hrs and preferably 1 hr to 24 hrs.
  • the reaction can be advantageously conducted in the presence of a base, including, for instance, an alkali metal alkoxide such as sodium methoxide, sodium ethoxide and potassium tert-butoxide; alkali metal hydroxide such as sodium hydroxide and potassium hydroxide; alkali metal carbonates such as sodium carbonate and potassium carbonate; alkali metal hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate; alkali metal phosphate such as sodium phosphate, and others.
  • a base including, for instance, an alkali metal alkoxide such as sodium methoxide, sodium ethoxide and potassium tert-butoxide; alkali metal hydroxide such as sodium hydroxide and potassium hydroxide; alkali metal carbonates such as sodium carbonate and potassium carbonate; alkali metal hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate; alkali metal phosphate such as sodium phosphate, and others.
  • the reaction can be advantageously conducted in the presence of oxidating agent, for instance, hydrogen peroxide, manganese dioxide, dimethyl dioxirane, sodium percarbonate, sodium perborate, oxone, and the others.
  • oxidating agent for instance, hydrogen peroxide, manganese dioxide, dimethyl dioxirane, sodium percarbonate, sodium perborate, oxone, and the others.
  • the reaction can be advantageously conducted in the presence of an acid including, for instance, trifluoroacetic acid, hydrochloric acid and sulfonic acid, and others.
  • an acid including, for instance, trifluoroacetic acid, hydrochloric acid and sulfonic acid, and others.
  • compound 2 can be prepared by the reaction of compound 1 (wherein L' represents leaving group including, for instance, halogen atom such as chlorine, bromine, or iodine atom; C 6-10 arylsulfonyloxy group such as benzenesulfonyloxy or p-toluenesulfonyloxy; C 1-4 alkylsulfonyloxy group such as methanesulfonyloxy; and halogen substituted C 1- alkylsulfonyloxy group such as trifluoromethanesulfonyloxy and the like, and R and R 5 are the same as defined above) with ethyl cyanoacetate using a base, for instance, sodium hydride.
  • L' represents leaving group including, for instance, halogen atom such as chlorine, bromine, or iodine atom
  • C 6-10 arylsulfonyloxy group such as benzenesulfonyloxy or p
  • the reaction may be carried out in a solvent including, for instance, ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2- dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; amides such as N, N-dimethylformamide (DMF), N, N-dimethylacetamide and N- methylpyrrolidone; sulfoxides such as dimethylsulfoxide (DMSO); alcohols such as methanol, ethanol, 1 -propanol, isopropanol and tert-butanol,; and others.
  • a solvent including, for instance, ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2- dimethoxyethane; aromatic hydrocarbons such as benzene, tolu
  • Compound 3 (wherein R and R 5 are the same as defined above) can be prepared by reducing nitro group of compound 2 using agent including, for instance, metals such as zinc and iron in the presence of acid including, for instance, hydrochloric acid and acetic acid.
  • agent including, for instance, metals such as zinc and iron in the presence of acid including, for instance, hydrochloric acid and acetic acid.
  • the reaction can be carried out without solvent or in a solvent including, for instance; aromatic hydrocarbons such as benzene, toluene and xylene, and others.
  • the reaction may be carried out, usually, at room temperature to 100 °C for 30 mins to 12 hrs.
  • Compound 4a (wherein R 1 represents amino, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 2-6 )alkynyl, halogen substituted (C 1-6 ) alkyl, cyano, cyano(C 1-6 )alkyl, (C 3-8 )cycloalkyl, nitro- (C ⁇ _ 6 )alkyl or fluoro and R 4 and R 5 are the same as defined above) can be prepared by the reaction of compound 3 with appropriate cyano compounds (R ⁇ CN) (wherein R 1' is the same as defined above).
  • the reaction can be carried out in a solvent including, for instance, alcohols such as methanol, ethanol, 1 -propanol, isopropanol and tert- butanol; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene, and others.
  • a solvent including, for instance, alcohols such as methanol, ethanol, 1 -propanol, isopropanol and tert- butanol; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene, and others.
  • the reaction may be carried out, usually,
  • Cyano compounds are commercially available or can be synthesized by conventional methods.
  • Compound 4b (wherein R 1 is hydrogen and R 4 and R 5 are the same as defined above) can be prepared by the reaction of compound 3 with ammonium formate in a solvent such as formamide. The reaction may be carried out, usually, at 40°C to 180°C for 2 hrs to two days. If desired, the resulting 4b can be further modified to introduce nitro group at the position of R 1 .
  • Ammonium formate and formamide are commercially available or can be synthesized by conventional methods.
  • the compound of formula (II) (wherein R 1 , R 4 and R 5 are the same as defined above and L represents leaving group including, for instance, halogen atom such as chlorine, bromine, or iodine atom; C 6-10 arylsulfonyloxy group such as benzenesulfonyloxy or p-toluenesulfonyloxy; C 1- alkylsulfonyloxy group such as methanesulfonyloxy; and halogen substituted C 1-4 alkylsulfonyloxy group such as trifluoro- methanesulfonyloxy and the like.) can be prepared for instance, by the reaction of compound 4 with appropriate halogenating reagent including, for instance, POCl 3 , PC1 5 , SOCl 2 , and the like; or can be prepared, for instance, by the reaction of compound 4 with appropriate sulfonyl chloride.
  • appropriate halogenating reagent including,
  • the reaction may be carried out without solvent or in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2- dichloroethane;such as ethers such as dioxane and tetrahydrofuran (THF) and 1,2- dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, and xylene, and others.
  • halogenated hydrocarbons such as dichloromethane, chloroform and 1,2- dichloroethane
  • ethers such as dioxane and tetrahydrofuran (THF) and 1,2- dimethoxyethane
  • aromatic hydrocarbons such as benzene, toluene, and xylene, and others.
  • two or more of the solvents selected from the listed above can be mixed and used.
  • the reaction can be advantageously conducted in the presence of a base, including, for instance, such as pyridine, triethylamine and N,N-diiso- propylethylamine, dimethylaniline, diethylaniline, and others.
  • a base including, for instance, such as pyridine, triethylamine and N,N-diiso- propylethylamine, dimethylaniline, diethylaniline, and others.
  • the reaction temperature is usually, but not limited to, about 40°C to 200°C and preferably about 20°C to 180°C
  • the reaction may be conducted for, usually, 30 minutes to 48 hrs and preferably 2 hr to 12 hrs.
  • halogenating reagents and sulfonyl chlorides are commercially available or can be synthesized by conventional methods.
  • Typical salts of the compound shown by the formula (I) include salts prepared by reaction of the compounds of the present invention with a mineral or organic acid, or an organic or inorganic base. Such salts are known as acid addition and base addition salts, successively.
  • Acids to form salts include inorganic acids such as, without limitation, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid like, and organic acids, such as, without limitation, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
  • inorganic acids such as, without limitation, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid like
  • organic acids such as, without limitation, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
  • Base addition salts include those derived from inorganic bases, such as, without limitation, ammonium hydroxide, alkaline metal hydroxide, alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, and organic bases, such as, without limitation, ethanolamine, triethylamine, tris(hydroxymethyl)aminomethane, and the like.
  • inorganic bases include, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
  • the compound of the present invention or a salts thereof, depending on its substituents, may be modified to form lower alkylesters or known other esters; and/or hydrates or other solvates. Those esters, hydrates, and solvates are included in the scope of the present invention.
  • the compound of the present invention may be administered in oral forms, such as, without limitation normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions. They may also be administered in parenteral forms, such as, without limitation, intravenous, intraperitoneal, subcutaneous, intramuscular, and the like forms, well-known to those of ordinary skill in the pharmaceutical arts.
  • the compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal delivery systems well-known to those of ordinary skilled in the art.
  • the dosage regimen with the use of the compounds of the present invention is selected by one of ordinary skill in the arts, in view of a variety of factors, including, without limitation, age, weight, sex, and medical condition of the recipient, the severity of the condition to be treated, the route of administration, the level of metabolic and excretory function of the recipient, the dosage form employed, the particular compound and salt thereof employed.
  • the compounds of the present invention are preferably formulated prior to administration together with one or more pharmaceutically-acceptable excipients. Excipients are inert substances such as, without limitation carriers, diluents, flavoring agents, sweeteners, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
  • compositions of the present invention are pharmaceutical formulation comprising a compound of the invention and one or more pharmaceutically- acceptable excipients that are compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • Pharmaceutical formulations of the invention are prepared by combining a therapeutically effective amount of the compounds of the invention together with one or more pharmaceutically-acceptable excipients.
  • the active ingredient may be mixed with a diluent, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper, or other container.
  • the carrier may serve as a diluent, which may be solid, semi-solid, or liquid material wliich acts as a vehicle, or can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • a diluent which may be solid, semi-solid, or liquid material wliich acts as a vehicle, or can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powder
  • the active ingredient may be combined with an oral, and non-toxic, pharmaceutically-acceptable carrier, such as, without limitation, lactose, starch, sucrose, glucose, sodium carbonate, mannitol, sorbitol, calcium carbonate, calcium phosphate, calcium sulfate, methyl cellulose, and the like; together with, optionally, disintegrating agents, such as, without limitation, maize, starch, methyl cellulose, agar bentonite, xanthan gum, alginic acid, and the like; and optionally, binding agents, for example, without limitation, gelatin, natural sugars, beta-lactose, corn sweeteners, natural and synthetic gums, acacia, tragacanth, sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like; and, optionally, lubricating agents, for example, without limitation, magnesium stearate, sodium stearate, stearic acid, sodium oleate, sodium benzoate,
  • the carrier may be a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient may be mixed with a carrier having binding properties in suitable proportions and compacted in the shape and size desired to produce tablets.
  • the powders and tablets preferably contain from about 1 to about 99 weight percent of the active ingredient which is the novel composition of the present invention.
  • Suitable solid carriers are magnesium carboxymethyl cellulose, low melting waxes, and cocoa butter.
  • Sterile liquid formulations include suspensions, emulsions, syrups and elixirs.
  • the active ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent, or a mixture of both sterile water and sterile organic solvent.
  • the active ingredient can also be dissolved in a suitable organic solvent, for example, aqueous propylene glycol.
  • a suitable organic solvent for example, aqueous propylene glycol.
  • Other compositions can be made by dispersing the finely divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.
  • the formulation may be in unit dosage form, which is a physically discrete unit containing a unit dose, suitable for administration in human or other mammals.
  • a unit dosage form can be a capsule or tablets, or a number of capsules or tablets.
  • a "unit dose" is a predetermined quantity of the active compound of the present invention, calculated to produce the desired therapeutic effect, in association with one or more excipients.
  • the quantity of active ingredient in a unit dose may be varied or adjusted from about 0.1 to about 1000 milligrams or more according to the particular treatment involved.
  • Typical oral dosages of the present invention when used for the indicated effects, will range from about 0.0 lmg ⁇ cg/day to about 100 mg/kg/day, preferably from 0.1 mg/kg/day to 30 mg/kg/day, and most preferably from about 0.5 mg/kg/day to about 10 mg/kg/day.
  • parenteral administration it has generally proven advantageous to administer quantities of about 0.001 to lOOmg /kg/day, preferably from 0.01 mg/kg/day to 1 mg/kg/day.
  • the compounds of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses, two, three, or more times per day. Where delivery is via transdermal forms, of course, administration is continuous.
  • MS MS data were recorded on a Micromass Platform LC with Shimadzu Phenomenex ODS column(4.6 mm ⁇ X 30 mm) flushing a mixture of acetonitrile- water (9:1 to 1:9) at 1 ml/min of the flow rate.
  • Mass spectra were obtained using electrospray (ES) ionization techniques (micromass Platform LC).
  • TLC was performed on a precoated silica gel plate (Merck silica gel 60 F-254).
  • Silica gel WAKO-gel C-200 (75-
  • a plasmid containing human MKK7 open reading frame was cloned into a pGEM-T Easy vector (Promega, Madison, WI) and further into a pGEX-6P-2 vector (Pharmacia) to construct human GST(Glutathione-S-transferase)-
  • MKK7 fusion protein This construct was coexpressed with human MEKKc (catalytic domain of MEKK (MEK (Map kinase kinase) kinase) on plasmid pBB131, in E.coli (BL21(DE3)pLysS).
  • MEKKc catalytic domain of MEKK (MEK (Map kinase kinase) kinase) on plasmid pBB131, in E.coli (BL21(DE3)pLysS).
  • the resulting GST-MKK7 was purified with the use of a glutathione column
  • GST-KN-SAPK ⁇ was purified with the use of glutathione column (Amersham Pharmacia Biotech AB, Uppsala, Sweden) according to the manufacturer's instruction. The purity of the protein was confirmed to be more than 90% by SDS-PAGE.
  • Test compounds (2.5 ⁇ l) at various concentrations (in 1% DMSO) were added to 15 ⁇ l of reaction buffer (20mM HEPES, 0.1M NaCl, 0.1 mM NasNO4, lOmM MgCk, ImM DTT, lmg/ml BSA, pH 7.5)) containing
  • a plasmid containing human MKK4 open reading frame was cloned into a pGEX-2T vector (Pharmacia) to construct human GST(Glutathione-S- transferase)-MKK4 fusion protein. This construct was coexpressed with human MEKKc (catalytic domain of MEKK on plasmid pBB131) in E.coli (BL21(DE3)pLysS).
  • the resulting GST-MKK4 was purified with the use of glutathione column (Amersham Pharmacia Biotech AB, Uppsala, Sweden) according to the manufacturer's instruction. The purity of the protein was confirmed to be more than 90% by SDS-PAGE.
  • GST-KN-SAPK ⁇ was purified with the use of glutathione column (Amersham Pharmacia Biotech AB, Uppsala, Sweden) according to the manufacturer's instruction. The purity of the protein was confirmed to be more than 90% by SDS-PAGE.
  • Biotinylation of the substrate protein was done using sulfo-NHS-LC Biotin according to the manufacturer's instructions (Pierce, Rockford, US)
  • Test compounds (5 ⁇ l) at various concentrations (in 1% DMSO) were added to 30 ⁇ l of reaction buffer (20mM HEPES, 0.1M NaCl, 0.1 mM Na3NO4, lOmM MgCk, ImM DTT, lmg/ml BSA, pH 7.5)) containing 0.5 ⁇ g/ml GST-MKK4 and 6 ⁇ M ATP.
  • reaction buffer (20mM HEPES, 0.1M NaCl, 0.1 mM Na3NO4, lOmM MgCk, ImM DTT, lmg/ml BSA, pH 7.5)
  • the kinase reaction was started by the addition of 25 ⁇ l assay buffer containing 0.48 ⁇ M SAPK ⁇ (biotinylated
  • huPBMC Human peripheral blood mononucleated cells isolated using mono-poly resolving medium (Dainippon Seiyaku, Osaka, Japan) were incubated with test compounds (various concentrations in 0.1% DMSO) for 1 hour in a 37°C CO2 incubator. Cells were then plated on 96 well plates (1x10s cell per well in 200 ⁇ l RPMI1640 cell culture medium) pre-coated for 3 hrs with 100 ⁇ l anti-CD3 antibody
  • interleukin- 2 IL-2
  • IFN- ⁇ interferon- ⁇
  • huPBMC Human peripheral blood mononucleated cells isolated using mono-poly resolving medium were either directly used for experiments (lxl 0s cells per well in 200 ⁇ l medium) or differentiated to dendritic cells (DC) in the presence of GM-SCF
  • TNF- ⁇ or IL-12 was induced by stimulation with LPS (B8, Sigma, Missouri, US) 10 ng/ml). 20 hrs later supernatant was removed and stored at -30°C in aliquots until further use.
  • TNF- ⁇ and IL-12 released from cell cultures were determined by commercially available ELISA (Genzyme Tech., Minneapolis, US) according to the manufacturer's instructions.
  • mice Male Balb/c mice (20-25 g body weight) were in injected with agonistic anti-CD3 Ab (Pharmingen, San Diego, US; 10 ⁇ g/mouse; clone 145-2C11) i.v. 5 minutes after compound application (i.v. in 10 % . 2 hrs post-challenge, mice were sacrificed and the serum cytokines IL-2, IL-4 and IFN- ⁇ were determined by ELISA (Genzyme Tech., Minneapolis, US) according to the manufacturer's instruction. Data represent mean values ⁇ SD of 5-6 animals each. * p ⁇ 0.05, ** p ⁇ 0.01 vs. vehicle control (V); Dunnett's test was used to detect differences among groups and statistics were performed using one-sided ANONA or Student's t-test if applicable.
  • MKK 7 kinase assay MKK 7 kinase assay
  • MKK4 kinase assay MKK4 kinase assay
  • the compounds of the present invention also show excellent selectivity, and strong activity in in vivo assays.
  • NBS N-bromosuccinimide
  • benzoyl peroxide 0.45 g
  • the reaction mixture was passed through a filter paper to remove resulting precipitates, that were washed with chloroform (50 ml). The filtrates were combined and washed with saturated sodium thiosulfite water solution and brine, successively.
  • Ethyl ⁇ -cyano-5-methoxycarbonyl-2-nitrophenylacetate (3.10 g) was dissolved in glacial acetic acid (30 ml) at 80°C Keeping the temperature, zinc powder (5.55 g) was added portionwise. The mixture was stirred at 90°C to 100°C for 1 h. After cooling to room temperature, the reaction mixture was passed through a filter paper to remove insoluble materials and washed with glacial acetic acid (10 ml). The filtrates were combined and evaporated in vacuo. The residue was dissolved in ethyl acetate (30 ml) and washed with saturated sodium bicarbonate water solution (30 ml X 3) and brine (30 ml), successively.
  • 6-carbamoyl-4-(l-piperidinyl)-9H-pyrimido[4,5-b]indole (0.028 g, 56%) as a colorless powder.
  • Example 1-4 to 1-32 were synthesized.
  • ethyl 2-amino-6-cyanoindole-3 -carboxylate was prepared according to the procedure described in Example 1-1. To a suspension of ethyl 2-amino-6-cyanoindole-3-carboxylate (0.96 g) and cyanamide (0.88 g) in 1,4-dioxane (50 ml) was added 36% hydrochloric acid (0.84 ml). The mixture was refluxed for 2 days and, after cooling to room temperature, concentrated in vacuo. The residue was washed with diethylether and triturated with methanol to give precipitates, that was collected by a paper filter and washed with methanol. The collected solid was dried at 85°C in vacuo to give a colorless solid (0.72 g, 66%).
  • Example 4-3 to 4-13 as shown in Table 4 were synthesized. Table 4
  • 6-benzyloxy-4-chloro-(9H)- pyrimido[4,5-b]indole hydrochloride (0.12 g, 0.355 mmol) was reacted with piperidine (1.5 mL) in 1,4-dioxane (5.0 mL) to give 6-benzyloxy ⁇ 4-(l- piperidino)-(9H)-pyrimido[4,5-b]indole as a pale orange solid (0.024 g, 18.8%).
  • Example 5 In the similar manners as described in Example5-1 above, the compounds in Example 5-2 to 5-59 as shown in Table 5 were synthesized. Table 5
  • Example 6-2 to 6-16 as shown in Table 6 were synthesized.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention porte sur des pyrimido[4,5-b]indoles utiles en tant que principe actif de compositions pharmaceutiques. Les pyrimido[4,5-b]indoles de la présente invention ont une activité inhibitrice sur MKK7 et MKK4 et peuvent s'utiliser dans la prévention et le traitement des maladies associées à l'activité des MKK7 et MKK4. Ces maladies comprennent des troubles inflammatoires et immunorégulateurs et des maladies telles que l'asthme, la dermatite atopique, la rhinite, la rhinite allergique, les maladies allergiques, la BPCO, le choc septique, l'arthrite, les maladies des articulations et les accidents du myocarde ainsi que des pathologies auto-immunes telles que la polyarthrite rhumatoïde, la maladie de Graves et l'athérosclérose. Les composés de la présente invention sont aussi utiles dans le traitement de l'ischémie, de la lésion myocardique, de l'hypertension pulmonaire, de l'insuffisance rénale, de la chorée de Huntington et de l'hypertrophie cardiaque ainsi que de maladies neurodégénératives telles que la maladie de Parkinson, la maladie d'Alzheimer et l'ischémie focale.
EP02777332A 2001-10-31 2002-10-29 Derives de pyrimido (4,5-b) indole Withdrawn EP1442039A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001334662 2001-10-31
JP2001334662A JP2003137886A (ja) 2001-10-31 2001-10-31 ピリミド［４，５−ｂ］インドール
GB0214544 2002-06-24
GB0214544A GB2390090A (en) 2002-06-24 2002-06-24 Pharmaceutically active 6-carbamoylpyrimido[4,5-b]indoles
PCT/EP2002/012057 WO2003037898A1 (fr) 2001-10-31 2002-10-29 Derives de pyrimido [4,5-b] indole

Publications (1)

Publication Number Publication Date
EP1442039A1 true EP1442039A1 (fr) 2004-08-04

Family

ID=26247088

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02777332A Withdrawn EP1442039A1 (fr) 2001-10-31 2002-10-29 Derives de pyrimido (4,5-b) indole

Country Status (5)

Country Link
EP (1) EP1442039A1 (fr)
JP (1) JP2005515173A (fr)
CA (1) CA2464934A1 (fr)
MX (1) MXPA04004019A (fr)
WO (1) WO2003037898A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2390090A (en) * 2002-06-24 2003-12-31 Bayer Ag Pharmaceutically active 6-carbamoylpyrimido[4,5-b]indoles
WO2004058764A1 (fr) * 2002-12-27 2004-07-15 Bayer Healthcare Ag Derives 4-phenyl-pyrimido [4,5-b]indoles
WO2006116733A2 (fr) * 2005-04-28 2006-11-02 Supergen, Inc. Inhibiteurs des proteines kinases
WO2009004329A1 (fr) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, et 9h-1,3,6,9-tétraaza-fluorènes en tant qu'inhibiteurs de la fonction kinase chk1
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
EP2247558B2 (fr) 2008-02-14 2024-07-03 Eli Lilly and Company Nouveaux agents d'imagerie pour la détection d'une dysfonction neurologique
AU2009329879A1 (en) 2008-12-23 2011-08-11 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
JP5699149B2 (ja) 2009-09-04 2015-04-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
WO2012012712A2 (fr) * 2010-07-23 2012-01-26 President And Fellows Of Harvard College Composés renforçant l'activité protéasome tricyclique
US9045485B2 (en) 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
CA2829939C (fr) 2011-03-15 2020-10-13 Trius Therapeutics, Inc. Inhibiteurs de la gyrase tricyclique
CA2849566C (fr) 2011-11-09 2021-02-09 Cancer Research Technology Limited Composes de type 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile et leur utilisation therapeutique
EP2806875B1 (fr) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Composés permettant de moduler l'activité de protéasome
NZ627188A (en) 2012-01-27 2015-12-24 Univ Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
ES2624307T3 (es) 2012-05-15 2017-07-13 Cancer Research Technology Ltd 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo y usos terapéuticos del mismo
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN104016985B (zh) * 2013-03-01 2017-11-03 华东理工大学 一种吡唑并嘧啶化合物及其用途
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
ES2788977T3 (es) * 2014-04-22 2020-10-23 Univ Montreal Compuestos y uso de los mismos en la expansión de células madre hematopoyéticas y/o células progenitoras hematopoyéticas
WO2016067009A1 (fr) * 2014-10-28 2016-05-06 Redx Pharma Plc Composés présentant une activité contre les bactéries et les mycobactéries
US10828329B2 (en) 2015-06-05 2020-11-10 Hema-Quebec Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof
RU2625316C1 (ru) * 2016-04-13 2017-07-13 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) 2-АМИНОЗАМЕЩЕННЫЕ 6-МЕТОКСИ-4-ТРИФТОРМЕТИЛ-9Н-ПИРИМИДО[4,5b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ПРЕДШЕСТВЕННИКИ
SG11201900515PA (en) 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors
CN107353288B (zh) * 2017-06-23 2019-10-18 吉林大学 4-乙胺(2-羧基)-9H-嘧啶并[4,5-b]吲哚及其制备方法
CN111788195B (zh) 2018-01-31 2023-11-21 海帕瑞吉尼克斯股份有限公司 用于促进肝脏再生或减少或预防肝细胞死亡的蛋白激酶mkk4抑制剂
WO2019161494A1 (fr) 2018-02-20 2019-08-29 Universite De Montreal Expansion de cellules nk et dc in vivo médiant une réponse immunitaire
US11731968B2 (en) 2018-06-21 2023-08-22 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3104246A1 (fr) 2018-07-16 2020-01-23 Heparegenix Gmbh Inhibiteurs de proteine kinase permettant de favoriser la regeneration du foie, ou de reduire ou de prevenir la mort des hepatocytes
WO2020072675A1 (fr) 2018-10-02 2020-04-09 Northwestern University Bêta-carbolines servant de modulateurs allostériques positifs du récepteur humain de la sérotonine 2c (5-ht2c)
WO2021018820A1 (fr) * 2019-07-29 2021-02-04 Heparegenix Gmbh Inhibiteurs de protéine kinase de pyrazolo-pyridine substitués par hétéroaryle pour favoriser la régénération du foie ou réduire ou prévenir la mort des hépatocytes
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
US11964981B1 (en) 2023-09-18 2024-04-23 King Faisal University Substituted pyrimido[4,5-b]indoles as CK2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
JPH11501623A (ja) * 1995-03-02 1999-02-09 ファルマシア・アンド・アップジョン・カンパニー ピリミド［４，５−ｂ］インドール
PT964865E (pt) * 1997-01-08 2003-06-30 Upjohn Co Aminas triciclicas farmaceuticamente activas

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03037898A1 *

Also Published As

Publication number Publication date
CA2464934A1 (fr) 2003-05-08
JP2005515173A (ja) 2005-05-26
WO2003037898A1 (fr) 2003-05-08
MXPA04004019A (es) 2004-07-08

Similar Documents

Publication Publication Date Title
EP1442039A1 (fr) Derives de pyrimido (4,5-b) indole
CA2551778C (fr) Derives d'acide imidazo[1,2-c]pyrimidinylacetique
EP1471057B1 (fr) Derivés de l'acid pyrimidinylacétique pour le traitment des maladies associées au CRTH2
US7745641B2 (en) Nitrogen-containing heterocyclic compound
JP4917041B2 (ja) タンパク質キナーゼ阻害剤としての化合物および組成物
EP0384349B1 (fr) Pyrroles substitués
WO2004058764A1 (fr) Derives 4-phenyl-pyrimido [4,5-b]indoles
CA2669686A1 (fr) Derives de purine substitues en 7, destines a l'immunosuppression
WO2001000207A1 (fr) Composes inhibiteurs de la src kinase
KR20070084191A (ko) 키나제 억제제로서의 １,４ 치환된 피라졸로피리미딘
TWI476200B (zh) 吡唑並嘧啶化合物及其充作ｐｄｅ１０抑制劑之用途
EP1948663A2 (fr) Pyrazolopyrimidines en tant que modulateurs de caseine kinase ii (ck2)
KR20080072886A (ko) ＥＰＨＢ 및 ＶＥＧＦＲ2 키나제 억제제로서의 3-(치환아미노)-피라졸로[3,4-ｄ]피리미딘
WO1996033196A1 (fr) Derives d'indole-3-carbonyle et d'indole-3-sulfonyle utilises en tant qu'antagonistes du facteur d'activation des plaquettes
Zhao et al. Discovery of novel Bruton’s tyrosine kinase (BTK) inhibitors bearing a pyrrolo [2, 3-d] pyrimidine scaffold
US6075021A (en) 1H-pyrido[3,4-b]indole-4-carboxamide derivatives, preparation and application thereof in therapeutics
WO2004099190A1 (fr) Nouveaux dérivés de benzimidazole substitués
GB2390090A (en) Pharmaceutically active 6-carbamoylpyrimido[4,5-b]indoles
US5371080A (en) Imidazoquinazoline compounds and their use
JP2003137886A (ja) ピリミド［４，５−ｂ］インドール
WO2009124965A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidin-2-ylamine comme inhibiteurs de pkc-thêta

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040601

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051130